Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Financing Respiratory Strategy

Verona Stock Soars After $200m Placement For COPD Drug

Fundraise Nearly Quadruples Market Cap

  • Interviews

Executive Summary

The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.

You may also be interested in...



UK Biotechs Look Destined To Remain Bit Players

Another promising British-based company, GW Pharma, has been acquired, this time by mid-sized US player Jazz. Is it a pipedream that a UK biotech could be in a position to pull off a $7bn takeover of its own or does it really not matter?

Itching To Succeed: UNION Buys LEO Pharma’s PDE4 Inhibitor Series

Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.

GSK Averts Strike At UK Sites

Table

View full table

Topics

Related Companies

Tags:
Financing Respiratory Strategy
UsernamePublicRestriction

Register

SC142607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By